Chester Ng

Dr. Chester Ng

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 August 2022 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
Daniel LarocheDaniel Laroche
Daniel Laroche
CNChester Ng
Chester Ng
GNGideon Nkrumah
Gideon Nkrumah
CNChester Ng
Chester Ng
Purpose. To determine the efficacy and safety of phacoemulsification, clear lensectomy, and the Hydrus microstent (Ivantis, Inc.) in Black and Afro-Latino glaucoma patients. Method. This is a retrospective nonrandomized study of 134 Black and Afro-Latino patients who underwent clear lensectomy with Hydrus stent implant for the treatment of glaucoma. For comprehensive analysis, patients were divided into mild, moderate, and advanced glaucoma. The evaluated parameters were reductions in the number of medications, intraocular pressure (IOP), mean deviation on visual field test, and visual acuity. Results. A total of 134 patients with 1-year follow-up were evaluated. At 1 year, the average number of medications significantly decreased from 2.5 ± 1.4 preoperatively to 0.43 ± 1.04 ( ) and IOP decreased from 14.4 ± 3.9 to 13.8 ± 3.10 ( ). 110 (82.1%) patients were medication-free at 1 year (n = 57, 83.8% mild glaucoma; n = 37, 92.5% moderate glaucoma; n = 16, 61.5% advanced glaucoma). There was stabilization of mean deviation on the visual field test (baseline, −8.28; 1 year, −8.28; ). The most reported adverse effects were transient IOP spike and hyphema (n = 7, 5.2%; n = 3, 2.2%, respectively); both events were self-resolving. No decline in vision or sight-threatening complications were reported at 1 year, and no additional surgeries were required. Conclusion. This 1-year retrospective study demonstrated the efficacy and safety of clear lensectomy and Hydrus stent implantation in decreasing medication burden while maintaining lower IOP in Black and Afro-Latino glaucoma patients.

8 September 2022 in Journal of Ophthalmology
Verified
Journal Article
Open access
Daniel LarocheDaniel Laroche
Daniel Laroche
AMAlexander Martin
Alexander Martin
ABAaron Brown
Aaron Brown
SSSohail Sakkari
Sohail Sakkari
CNChester Ng
Chester Ng
Mispositioned Hydrus Microstents: A Case Series Imaged with NIDEK GS-1 Gonioscope: Introduction. The Hydrus microstent has become a common procedure in glaucoma surgery intended to improve outcomes of cataract surgery to lower intraocular pressure. Despite proper placement, this device can subsequently be noted to not be in the proper position. In this case series, we report mispositioned Hydrus microstents in five different patients and use NIDEK GS-1 gonioscopy. Case Report. We report five different patients who had cataract surgery and who were subsequently noted to have mispositioned Hydrus stents. No stents needed to be removed. All patients had improved vision and stable visual fields, and none required secondary surgery. Management and Outcome. In each case of mispositioned stents, vision was significantly improved and there was no inflammation or other complications noted. Discussion. Hydrus stents can be noted to be mispositioned during the post-operative period after successful insertion. This can often be well tolerated requiring no further intervention.

24 January 2023 in Therapeutic Advances in Ophthalmology
Verified
Journal Article
Open access
Daniel LarocheDaniel Laroche
Daniel Laroche
GNGideon Nkrumah
Gideon Nkrumah
CNChester Ng
Chester Ng
Background: Suprachoroidal surgery can lower intraocular pressure and medication use. There is currently no commercial suprachoroidal product on the market. Here, we report our 1 year results of a novel ciliary sulcus suprachoroidal microtube technique. Purpose: To determine the real-world efficacy of intrascleral ciliary sulcus suprachoroidal microtube technique in Black and Afro-Latinx patients with glaucoma refractory to topical ocular hypertensive medications. Methods: A retrospective non-comparative single center study of 36 Black and Afro-Latinx patients with glaucoma and pseudophakia who underwent intrascleral ciliary sulcus suprachoroidal microtube surgery for glaucoma as a stand-alone procedure at a single practice. Investigated parameters were number of medications, visual acuity (VA), intraocular pressure (IOP), mean deviation on visual field (VF) test. Success was defined as (a) IOP ⩽ 15 mmHg and or ⩾ 20% reduction in IOP and (b) a reduction in number of medications. We used paired t-test to compare baseline and follow-up parameters. Results: We reviewed a total of 36 patients who had undergone the procedure. Twenty had success with 12-month follow-up in the study. The mean number of medications decreased significantly from 4.2 ± 1.0 preoperatively to 2.4 ± 1.7 in 12 months ( p = 0.021) with five patients being medication free. In addition, the IOP decreased significantly from 21 ± 8.2 to 13.5 ± 4.4 mmHg ( p = 0.032). In the 20 patients who had 12-month follow-up, the VA remained stable from Log Mar 0.62 ± 0.6–0.46 ± 0.6 ( p = 0.052). VF in patients with successful procedure (no further interventions) remained stable from baseline mean deviation of –16.53 ± 10.04 to –16.82 ± 9.80 dB at 6–12 months. Adverse effects were transient and included IOP spike, hypotony, hyphema, and cornea edema that were treated and resolved. Conclusions: This 12-month retrospective study demonstrated that intrascleral ciliary sulcus suprachoroidal microtube surgery can reduce IOP and medication burden in pseudophakic patients with glaucoma. However, despite several successes, surveillance should take place for IOP spikes, possible tube obstruction, and need for additional glaucoma surgery.

24 February 2023 in Journal of the National Medical Association
Verified
Journal Article
Open access
Daniel LarocheDaniel Laroche
Daniel Laroche
KRKara Rickford
Kara Rickford
JSJosé Sinon
José Sinon
ABAaron Brown
Aaron Brown
CNChester Ng
Chester Ng
SSSohail Sakkari
Sohail Sakkari
Objectives: The purpose of this report is to demonstrate the patient education ability and benefits in treating glaucoma and preventing blindness with the NIDEK GS-1 Gonioscope and earlier surgical intervention with cataract surgery/lensectomy and microinvasive glaucoma surgery (MIGS). Methods: This data was collected using a NIDEK GS-1 Gonioscope. Informed consent was obtained from all participants following explanation of possible risks. Results and Discussion: NIDEK GS-1 automated gonioscopy offers many advantages, including (1) the ability to capture high quality, 360-degree chromatic documentation of the iridocorneal angle and trabecular meshwork, (2) improved patient education on the condition at hand through images; and (3) visualization of the change in the angle and trabecular meshwork before and after surgical intervention in patients with glaucoma. Conclusion and Implications: Gonioscopic imaging is helpful in educating patients on the anatomy of the angle and how its anatomical configuration can contribute to glaucoma. It also gives clinicians a supplementary tool to document features of the ICA; to evaluate anatomical changes before and after surgical treatment of glaucoma and cataracts; and to demonstrate to patients how a specific surgical device or technique is controlling their intraocular pressure (IOP).

1 August 2020 in Journal of the National Medical Association
Verified
Journal Article
Closed access
Daniel LarocheDaniel Laroche
Daniel Laroche
ABAaron Brown
Aaron Brown
CNChester Ng
Chester Ng